GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkermes PLC (NAS:ALKS) » Definitions » Cyclically Adjusted PS Ratio

Alkermes (Alkermes) Cyclically Adjusted PS Ratio : 3.37 (As of Apr. 27, 2024)


View and export this data going back to 1991. Start your Free Trial

What is Alkermes Cyclically Adjusted PS Ratio?

As of today (2024-04-27), Alkermes's current share price is $24.68. Alkermes's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $7.32. Alkermes's Cyclically Adjusted PS Ratio for today is 3.37.

The historical rank and industry rank for Alkermes's Cyclically Adjusted PS Ratio or its related term are showing as below:

ALKS' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.54   Med: 8.67   Max: 23.5
Current: 3.37

During the past years, Alkermes's highest Cyclically Adjusted PS Ratio was 23.50. The lowest was 2.54. And the median was 8.67.

ALKS's Cyclically Adjusted PS Ratio is ranked worse than
67.66% of 736 companies
in the Drug Manufacturers industry
Industry Median: 2.06 vs ALKS: 3.37

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Alkermes's adjusted revenue per share data for the three months ended in Dec. 2023 was $2.262. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $7.32 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Alkermes Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Alkermes's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alkermes Cyclically Adjusted PS Ratio Chart

Alkermes Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.99 3.59 3.69 3.70 3.79

Alkermes Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.70 3.89 4.10 3.59 3.79

Competitive Comparison of Alkermes's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Alkermes's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alkermes's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alkermes's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Alkermes's Cyclically Adjusted PS Ratio falls into.



Alkermes Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Alkermes's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=24.68/7.32
=3.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alkermes's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Alkermes's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=2.262/120.1096*120.1096
=2.262

Current CPI (Dec. 2023) = 120.1096.

Alkermes Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.908 100.573 1.084
201406 0.994 100.773 1.185
201409 1.097 100.474 1.311
201412 1.192 99.576 1.438
201503 1.089 99.975 1.308
201506 1.017 100.573 1.215
201509 1.021 100.274 1.223
201512 1.085 99.676 1.307
201603 1.039 99.676 1.252
201606 1.290 101.072 1.533
201609 1.189 100.274 1.424
201612 1.403 99.676 1.691
201703 1.256 100.374 1.503
201706 1.427 100.673 1.703
201709 1.414 100.474 1.690
201712 1.790 100.075 2.148
201803 1.458 100.573 1.741
201806 1.963 101.072 2.333
201809 1.601 101.371 1.897
201812 2.030 100.773 2.420
201903 1.427 101.670 1.686
201906 1.783 102.168 2.096
201909 1.624 102.268 1.907
201912 2.618 102.068 3.081
202003 1.557 102.367 1.827
202006 1.558 101.769 1.839
202009 1.666 101.072 1.980
202012 1.759 101.072 2.090
202103 1.575 102.367 1.848
202106 1.853 103.364 2.153
202109 1.822 104.859 2.087
202112 1.832 106.653 2.063
202203 1.714 109.245 1.884
202206 1.686 112.734 1.796
202209 1.536 113.431 1.626
202212 1.854 115.425 1.929
202303 1.742 117.618 1.779
202306 3.599 119.611 3.614
202309 2.216 120.708 2.205
202312 2.262 120.110 2.262

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alkermes  (NAS:ALKS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Alkermes Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Alkermes's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alkermes (Alkermes) Business Description

Traded in Other Exchanges
Address
1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.
Executives
Cato T Laurencin director C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
Christian Todd Nichols officer: SVP, Chief Commercial Officer 852 WINTER STREET, WALTHAM MA 02451
Nancy Wysenski director 2200 SUNBURST STREET, CHATSWORTH CA 90401
Daglio David Angelo Jr. director ALKERMES, 852 WINTER STREET, WALTHAM MA 02451
Christopher I Wright director C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Michael J Landine officer: SVP, Corp Dev., Alkermes, Inc. 88 SIDNEY ST, CAMBRIDGE MA 021394136
Richard F Pops director, officer: Director and CEO, Alkermes plc 10555 SCIENCE CENTER DR, SAN DIEGO CA 92121
Shane Cooke officer: President, Alkermes plc TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
Blair Curtis Jackson officer: EVP, Chief Operating Officer 852 WINTER STREET, WALTHAM MA 02451
Snyderman Nancy Lynn Md director 37 PHEASANT HILL ROAD, PRINCETON NJ 08540
Craig C. Hopkinson officer: SVP, Med Dev/Med Affairs, CMO 852 WINTER STREET, WALTHAM MA 02451
Emily Peterson Alva director C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Iain Michael Brown officer: VP, Finance & CAO 14 ROYALSTON AVENUE, WINCHESTER MA 01890
Brian P Mckeon director IDEXX LABORATORIES, ONE IDEXX DRIVE, WESTBROOK ME 04092
David Joseph Gaffin officer: SVP, CLO, Alkermes, Inc. 852 WINTER STREET, WALTHAM MA 02451